logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
KPRX
Kiora Pharmaceuticals, Inc.
2.62
1 x 2.60
9 x 2.64
bid
ask
+
0.04
1.55%
undefined @ 04:00 PM
2.62 +0.00 (0.00%)
Ytd32.99%
1y6.94%
2.56
day range
2.64
1.76
52 week range
3.01
Open2.57Prev Close2.58Low2.56High2.64Mkt Cap11.61M
Vol12.44KAvg Vol29.38KEPS-2.51P/E-1.04Forward P/E-1.48
Beta-0.29Short Ratio0.27Inst. Own48.34%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg2.57200-d Avg2.311yr Est40.50

KPRX News

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com
Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, Califfornia--(Newsfile Corp. - August 7, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPR

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
newsfilecorp.com
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
newsfilecorp.com
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Pre

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epil

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
newsfilecorp.com
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today r

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
newsfilecorp.com
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase

Encinitas, California--(Newsfile Corp. - April 14, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) toda

Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)
defenseworld.net
Financial Comparison: Cronos Group (NASDAQ:CRON) & Kiora Pharmaceuticals (NASDAQ:KPRX)

Cronos Group (NASDAQ: CRON - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Rep

12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Kiora Pharmaceuticals Announces Management Team Changes
newsfilecorp.com
Kiora Pharmaceuticals Announces Management Team Changes

Encinitas, California--(Newsfile Corp. - April 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)

Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
newsfilecorp.com
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Di

Encinitas, California--(Newsfile Corp. - March 25, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
newsfilecorp.com
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference

Encinitas, California--(Newsfile Corp. - February 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: K

Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)
defenseworld.net
Financial Review: Kiora Pharmaceuticals (NASDAQ:KPRX) & Stevanato Group (NYSE:STVN)

Stevanato Group (NYSE: STVN - Get Free Report) and Kiora Pharmaceuticals (NASDAQ: KPRX - Get Free Re

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
newsfilecorp.com
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) ha

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
newsfilecorp.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

Earnings Scheduled For November 7, 2025
benzinga.com
Earnings Scheduled For November 7, 2025

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
newsfilecorp.com
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Activel

Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders
prnewswire.com
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New

ENCINITAS, Calif. and WASHINGTON D.C.

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
newsfilecorp.com
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KP

Kiora (KPRX) Q2 Revenue Falls 100%
fool.com
Kiora (KPRX) Q2 Revenue Falls 100%

Kiora (KPRX) Q2 Revenue Falls 100%

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
newsfilecorp.com
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active

Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
newsfilecorp.com
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocula

Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX)
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 164 companies achieved new lows for the year.
benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 298 companies achieved new lows for the year.
benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 64 companies achieved new lows for the year.
benzinga.com
Why Nikola Dropped Over 9%; Here Are 66 Biggest Movers From Yesterday

Gainers Mobile Global Esports Inc. (NASDAQ: MGAM) shares surged 103.9% to settle at $5.30 on Tues
benzinga.com
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022

 
benzinga.com
Stocks That Hit 52-Week Lows On Friday

  During Friday's session, 61 companies made new 52-week lows.
benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  On Thursday, 550 companies achieved new lows for the year.
benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

    Tuesday's session saw 729 companies set new 52-week lows.